BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 8989723)

  • 1. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma.
    Lissoni P; Brivio O; Brivio F; Barni S; Tancini G; Crippa D; Meregalli S
    J Pineal Res; 1996 Nov; 21(4):239-42. PubMed ID: 8989723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
    Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
    Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphatic flow is mostly preserved after sentinel lymph node biopsy in primary cutaneous malignant melanoma.
    Yokota K; Sawada M; Matsumoto T; Hasegawa Y; Kono M; Akiyama M
    J Dermatol Sci; 2015 May; 78(2):101-7. PubMed ID: 25771166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival.
    Retsas S; Quigley M; Pectasides D; Macrae K; Henry K
    Cancer; 1994 Apr; 73(8):2119-30. PubMed ID: 8156517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.
    Henderson MA; Burmeister BH; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
    Lancet Oncol; 2015 Sep; 16(9):1049-1060. PubMed ID: 26206146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reduction of relapse in the radiation area by adjuvant lymph-node field radiotherapy in metastatic malignant melanoma patients at high risk of recurrence].
    Gutzmer R; Christiansen H
    Strahlenther Onkol; 2016 Mar; 192(3):190-2. PubMed ID: 26795392
    [No Abstract]   [Full Text] [Related]  

  • 7. Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
    Koster BD; van den Hout MFCM; Sluijter BJR; Molenkamp BG; Vuylsteke RJCLM; Baars A; van Leeuwen PAM; Scheper RJ; Petrousjka van den Tol M; van den Eertwegh AJM; de Gruijl TD
    Clin Cancer Res; 2017 Oct; 23(19):5679-5686. PubMed ID: 28972083
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
    Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
    Fisher SR
    Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
    Tas F; Erturk K
    Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
    Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
    Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
    Agrawal S; Kane JM; Guadagnolo BA; Kraybill WG; Ballo MT
    Cancer; 2009 Dec; 115(24):5836-44. PubMed ID: 19701906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
    Fujisawa Y; Otsuka F;
    Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of lymph nodes in head and neck melanoma: a retrospective study of 25 cases].
    Ricard AS; Majoufre-Lefebvre C; Delaunay M; Siberchicot F; Zwetyenga N
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):505-8. PubMed ID: 17900640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities.
    Kroon HM; van der Bol WD; Tonks KT; Hong AM; Hruby G; Thompson JF
    Ann Surg Oncol; 2018 Nov; 25(12):3476-3482. PubMed ID: 30116948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy.
    Hamming-Vrieze O; Balm AJ; Heemsbergen WD; Hooft van Huysduynen T; Rasch CR
    Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):795-800. PubMed ID: 19687401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.